文献速递神经免疫

那他珠单抗对多发性硬化患者外周免疫细胞动态影响的可逆性

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
PubMed 文献 · Neurology · 2017-09-15

本研究基于AFFIRM和RESTORE研究数据,分析多发性硬化患者中断那他珠单抗治疗后药效学标志物的可逆性。结果显示,末次给药后8周淋巴细胞计数开始显著下降,约16周恢复至治疗前水平,所有免疫细胞亚群及功能标志物呈现类似可逆性,提示那他珠单抗生物效应可逆。

要点

  • 那他珠单抗治疗期间淋巴细胞计数升高,中断后8周开始下降,约16周恢复至治疗前水平。
  • 免疫细胞亚群、α4整合素表达/饱和度和sVCAM-1变化均呈现类似可逆性。
  • 该可逆性有助于临床医生制定多发性硬化治疗顺序决策。

核心结论

  • 那他珠单抗对外周免疫细胞和药效学标志物的影响是可逆的,末次给药后约16周恢复至未治疗水平。

研究设计与样本

  • 基于AFFIRM研究(每12周采集,共116周)和RESTORE研究(每4周采集,共28周)的药代动力学/药效学数据。

主要发现

  • 那他珠单抗治疗患者血淋巴细胞计数从2.1×10^9/L升至3.5×10^9/L。
  • 末次给药后8周起,中断治疗组淋巴细胞计数显著低于持续治疗组(3.1×10^9/L vs 3.5×10^9/L;p=0.031),16周起平台至治疗前水平。
  • 所有测量的细胞亚群、α4整合素表达/饱和度及sVCAM变化均显示类似可逆性。
  • 淋巴细胞计数保持在正常范围内。
  • 离体VCAM-1结合在末次给药后约16周内增加后平台,提示免疫细胞功能可逆。

关键数值与推荐

  • 药效学标志物在停用那他珠单抗后约16周逆转(Class III证据)。

临床怎么用

  • 了解那他珠单抗生物效应的可逆时间过程可能帮助临床医生做出治疗顺序决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption. METHODS: Pharmacokinetic/pharmacodynamic data were collected in the Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis (AFFIRM) (every 12 weeks for 116 weeks) and Randomized Treatment Interruption of Natalizumab (RESTORE) (every 4 weeks for 28 weeks) studies. Serum natalizumab and soluble vascular cell adhesion molecule-1 (sVCAM-1) were measured using immunoassays. Lymphocyte subsets, α4-integrin expression/saturation, and vascular cell adhesion molecule-1 (VCAM-1) binding were assessed using flow cytometry. RESULTS: Blood lymphocyte counts (cells/L) in natalizumab-treated patients increased from 2.1 × 109 to 3.5 × 109. Starting 8 weeks post last natalizumab dose, lymphocyte counts became significantly lower in patients interrupting treatment than in those continuing treatment (3.1 × 109 vs 3.5 × 109; p = 0.031), plateauing at prenatalizumab levels from week 16 onward. All measured cell subpopulation, α4-integrin expression/saturation, and sVCAM changes demonstrated similar reversibility. Lymphocyte counts remained within the normal range. Ex vivo VCAM-1 binding to lymphocytes increased until ≈16 weeks after the last natalizumab dose, then plateaued, suggesting reversibility of immune cell functionality. The temporal appearance of gadolinium-enhancing lesions was consistent with pharmacodynamic marker reversal. CONCLUSIONS: Natalizumab's effects on peripheral immune cells and pharmacodynamic markers were reversible, with changes starting 8 weeks post last natalizumab dose; levels returned to those observed/expected in untreated patients ≈16 weeks post last dose. This reversibility differentiates natalizumab from MS treatments that require longer reconstitution times. Characterization of the time course of natalizumab's biological effects may help clinicians make treatment sequencing decisions. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the pharmacodynamic markers of natalizumab are reversed ≈16 weeks after stopping natalizumab.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017. PMID: 28916537. doi:10.1212/WNL.0000000000004485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。